© Reuters. FILE PHOTO: Vials labelled “COVID-19 Coronavirus Vaccine” and sryinge are seen in front of displayed J&J logo in this illustration

PARIS (Reuters) – France’s health regulator said on Friday it had approved Johnson & Johnson (NYSE:)’s single-dose COVID-19 vaccine for use in France, a day after it was approved by the European Union authorities.

“The COVID-19 Janssen vaccine can be used on people from the age of 18 … within the framework of the French vaccination strategy, including for people aged 65 and older and who might have illnesses,” the Haute Autorite de Sante (HAS) said in a statement.

HAS said the vaccine was efficient and well tolerated by patients. It will be the fourth vaccine on the French market.

The European Medicines agency (EMA) approved the Johnson & Johnson vaccine on Thursday, paving the way for the first shots to be delivered in a month.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link